Review: AT 1-receptor blockade in experimental myocardial ischaemia/reperfusion

Linder C. , Heusch G. : ACE inhibitors for the treatment of myocardial ischemia? Cardiovasc Drugs Ther1990;4:1375-84.

Lindpaintner K. , Wilhelm MJ , Jin M. et al. Tissue renin-angiotensin systems: Focus on the heart. J Hypertens1987 ;5 (suppl 2):S33-S38.

HirschAT , Talsness CE , Schunkert H. , Paul M. , Dzau VJ Tissue-specific activation of cardiac angiotensin converting enzyme in experimental heart failure. Circ Res1991;69:475-82.

Danser,AHJ Saris JJ , Schuijt MP , van Kats JP : Is there a local renin-angiotensin system in the heart? Cardiovasc Res1999;44:252-65.

Ertl G. , Kloner RA , Alexander RW , Braunwald E. Limitation of experimental infarct size by an angiotensin-converting enzyme inhibitor. Circulation1982;65:40-8.

McAlpine HM , Cobbe SM Neuroendocrine changes in acute myocardial infarction. Am J Med1988;84 (suppl 3A):61-6

Noda K. , Sasaguri M. , Ideishi M. , Ikeda M. , Arakawa K. Role of locally formed angiotensin II and bradykinin in the reduction of myocardial infarct size in dogs. Cardiovasc Res1993;27: 334-40.

Balcells E. , Meng QC , Johnson J. r. WH, Oparil S, Dell'Italia LJ. Angiotensin II formation from ACE and chymase in human and animal hearts: methods and species considerations. Am J Physiol1997;42:H1769-H1774.

Hollenberg NK Implications of species difference for clinical investigation. Studies on the renin-angiotensin system. Hypertension2000;35 [part 2]:150-4.

Baumgarten CR , Linz WL , Kunkel G. , Schölkens BA , Wiemer G. Ramiprilat increases bradykinin outflow from isolated hearts of rat. Br J Pharmacol1993 ;108:293-5.

Timmermans Pbmwm , Wong PC , Chiu AT et al. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev1993 ;45:205-51.

Paradis P. , Dali-Youcef N. , Paradis FW , Thibault G. , Nemer M. Overexpression of angiotensin II type I receptor in cardiomyocytes induces cardiac hypertrophy and remodeling. Proc Natl Acad Sci USA2000;97:931-6.

Mukoyama M. , Nakajima M. , Horiuchi M. , Sasamura H. , Pratt RE , Dzau VJ Expression cloning of type 2 angiotensin II receptor reveals a unique class of seven-transmembrane receptors. J Biol Chem1993;268:24539-42.

Scheuer DA , Perrone MH Angiotensin type 2 receptors mediate depressor phase of biphasic pressure response to angiotensin. Am J Physiol1993 ;33:R917-R923.

Akishita M. , Yamada H. , Dzau VJ , Horiuchi M. Increased vasoconstrictor response of the mouse lacking angiotensin II Type 2 receptor. Biochem Biophys Res Commun1999;261:345-9. 16. HunleyTE , Tamura M. , Stoneking BJ et al.The angiotensin type II receptor tonically inhibits angiotensin-converting enzyme in AT2 null mutant mice. Kidney Int2000;57:570-7.

Stoll M. , Steckelings UM , Bottari SP , Metzger R. , UngerT. The angiotensin AT2-receptor mediates inhibition of cell proliferation in coronary endothelial cells. J Clin Invest1995;95:651-7.

Hübner R. , Högemann AM , Sunzel M. , Riddell JG Pharmacokinetics of candesartan after single and repeated doses of candesartan cilexetil in young and elderly healthy volunteers. J Hum Hypertens1997; 11(Suppl 2):S19-S25.

Liu Y. -H, Yang X. -P, Sharov VG , Nass O. , Sabbah HH , Peterson E. , Carretero OA Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure. Role of kinins and angiotensin II type 2 receptors. J Clin Invest1997;99:1926-35.

Wiemer G. , Schölkens BA , Busse R. , Wagner A. , Heitsch H. , Linz W. The functional role of angiotensin II-subtype AT2-receptors in endothelial cells and isolated ischemic rat hearts. Pharm Pharmacol Lett1993;3:24-7.

Seyedi N. , Xu XB , Nasjletti A. , Hintze TH Coronary kinin generation mediates nitric oxide release after angiotensin receptor stimulation. Hypertension1995; 26:164-70.

Carey RM , Jin X. -H, Wang Z. -Q, Siragy HM Nitric oxide: a physiological mediator of the type 2 (AT2) angiotensin receptor . Acta Physiol Scand2000;168:65-71.

Kuga T. , Mohri M. , Egashira K. et al. Bradykinin-induced vasodilation of human coronary arteries in vivo: Role of nitric oxide and angiotensin-converting enzyme. J Am Coll Cardiol1997;30:108-12.

Martorana PA , Kettenbach B. , Breipohl G. , Linz W. , Schölkens BA Reduction of infarct size by local angiotensin-converting enzyme inhibition is abolished by a bradykinin antagonist. Eur J Pharmacol1990;182:395-6.

Werrmann JG , Cohen SM Comparison of effects of angiotensin-converting enzyme inhibition with those of angiotensin II receptor antagonism on functional and metabolic recovery in postischemic working rat heart as studied by [31P] nuclear magnetic resonance. J Cardiovasc Pharmacol1994;24:573-86.

Werrmann JG , Cohen SM Use of losartan to examine the role of the cardiac renin-angiotensin system in myocardial dysfunction during ischemia and reperfusion. J Cardiovasc Pharmacol1996 ;27:177-82.

Paz Y. , Gurevitch J. , Frolkis I. et al. Effects of an angiotensin II antagonist on ischemic and nonischemic isolated rat hearts. Ann Thorac Surg1998;65:474-9.

Ford WR , Clanachan AS , Jugdutt BI Opposite effects of angiotensin AT1 and AT2 receptor antagonists on recovery of mechanical function after ischemia-reperfusion in isolated working rat hearts. Circulation1996;94:3087-9.

Massoudy P. , Becker BF , Gerlach E. Bradykinin accounts for improved postischemic function and decreased glutathione release of guinea pig heart treated with the angiotensin-converting enzyme inhibitor ramiprilat . J Cardiovasc Pharmacol1994;23:632-9.

Dörge H. , Behrends M. , Schulz R. , Jalowy A. , Heusch G. Attenuation of myocardial stunning by AT1receptor antagonist candesartan . Basic Res Cardiol1999;94:208-14.

van Gilst WH , de Graeff PA , Wesseling H. , de Langen CDJ. Reduction of reperfusion arrhythmias in the ischemic isolated rat heart by angiotensin converting enzyme inhibitors:A comparison of captopril, enalapril, and HOE 498. J Cardiovasc Pharmacol1986;8:722-8.

Ehring T. , Baumgart D. , Krajcar M. , Hümmelgen M. , Kompa S. , Heusch G. Attenuation of myocardial stunning by the ACE-inhibitor ramiprilat through a signal cascade of bradykinin and prostaglandins, but not nitric oxide. Circulation1994;90:1368-85.

Hohlfeld T. , Strobach H. , Schrör K. Stimulation of prostacyclin synthesis by defibrotide: Improved contractile recovery from myocardial `stunning` . J Cardiovasc Pharmacol1991;17:108-15.

Shimizu M. , Wang Q. -D, Sjöquist P-O. , Rydén L. The angiotensin II AT1-receptor antagonist candesartan improves functional recovery and reduces the no-reflow area in reperfused ischemic rat hearts . J Cardiovasc Pharmacol1999;34:78-81.

Yoshiyama M. , Kim S. , Yamagishi H. et al. Cardioprotective effect of the angiotensin II type 1 receptor antagonist TCV-116 on ischemia-reperfusion injury. Am Heart J1994;128:1-6.

Wang Q. - D. Sjöqist P-O. Effects of the insurmountable angiotensin AT1 receptor antagonist candesartan and the surmountable antagonist losartan on ischemia/reperfusion injury in rat hearts. Eur J Pharmacol1999 ;380:13-21.

Hoshida S. , Yamashita N. , Kuzuya T. , Hori M. Differential effects of long-term renin-angiotensin system blockade on limitation of infarct size in cholesterol-fed rabbits. Atherosclerosis2000;149:287-94.

Preckel B. , Schlack W. , González M. , Obal D. , Bathel H. , Thämer V. Influence of the angiotensin II AT1 receptor antagonist irbesartan on ischemia/reperfusion injury in the dog heart. Basic Res Cardiol2000;95:404-12.

Hartman JC , Hullinger TG , Wall TM , Shebuski RJ Reduction of myocardial infarct size by ramiprilat is independent of angiotensin II synthesis inhibition. Eur J Pharmacol1993 ;234:229-36.

Liu Y. , Tsuchida A. , Cohen MV , Downey JM Pretreatment with angiotensin II activates protein kinase C and limits myocardial infarction in isolated rabbit hearts. J Mol Cell Cardiol1995;27:883-92.

Diaz RJ , Wilson GJ Selective blockade of AT1 angiotensin II receptors abolishes ischemic preconditioning in isolated rabbit hearts. J Mol Cell Cardiol1997;29:129-39.

Shimizu M. , Wang Q. -D, Sjöquist P-O. , Ryden L. Angiotensin II type 1 receptor blockade with candesartan protects the porcine myocardium from reperfusion-induced injury. J Cardiovasc Pharmacol1998;32:231-8.

Shimizu M. , Wang Q. -D, Sjöquist P-O. , Rydén L. The angiotensin II AT1 receptor antagonist candesartan at antihypertensive plasma concentrations reduces damage induced by ischemia-reperfusion. Cardiovasc Drugs Ther1999;13:347-53.

Shimizu M. , Wang Q. -D, Sjöquist P-O. , Ryden L. Combination of a calcium antagonist, a lipid peroxidation inhibitor , and an angiotensin AT1-receptor antagonist provides additive myocardial infarct size-limiting effect in pigs. J Cardiovasc Pharmacol1999;34:512-7.

JalowyA, Schulz R. , Dörge H. , Behrends M. , Heusch G. Infarct size reduction by AT1-receptor blockade through a signal cascade of AT2-receptor activation, bradykinin and prostaglandins in pigs. J Am Coll Cardiol1998;32:1787-96.

Weidenbach R. , Schulz R. , Gres P. , Behrends M. , Post H. , Heusch G. Enhanced reduction of myocardial infarct size by combined ACE inhibition and AT1-receptor antagonism . BrJPharmacol2000; 131:138-44.

Liu Y. -H, Yang X. -P, Sharov VG , Sigmon DH , Sabbah HN , Carretero OA Paracrine systems in the cardioprotective effect of angiotensin-converting enzyme inhibitors on myocardial ischemia/reperfusion injury in rats. Hypertension1996;27:7-13.

Sladek T. , Sladkova J. , Kolar F. et al. The effect of AT1 receptor antagonist on chronic cardiac response to coronary artery ligation in rats. Cardiovasc Res1996;31:568-76.

Richard V. , Ghaleh B. , Berdeaux A. , Giudicelli J-F. Comparison of the effects of EXP3174, an angiotensin II antagonist and enalaprilat on myocardial infarct size in anaesthetized dogs . Br J Pharmacol1993;110:969-74.

Zhu B. -Q, Sun Y. -P, Sievers RE et al. Comparative effects of pretreatment with captopril and losartan on cardiovascular protection in a rat model of ischemia-reperfusion. J Am Coll Cardiol2000;35:787-95.

Xu Y. , Menon V. , Jugdutt BI Cardioprotection after angiotensin II type 1 blockade involves angiotensin II type 2 receptor expression and activation of protein kinase C-e in acutely reperfused myocardial infarction in the dog. Effect of UP269-6 and losartan on AT1- and AT2-receptor expression and IP3 receptor and PKCe proteins. JRAAS2000;1:184-95.

Schwarz ER , Montino H. , Fleischhauer J. , Klues HG , vom Dahl J. , Hanrath P. Angiotensin II receptor antagonist EXP 3174 reduces infarct size comparable with enalaprilat and augments preconditioning in the pig heart. Cardiovasc Drugs Ther1997;11:687-95.

Hartman JC , Wall TM , Hullinger TG , Shebuski RJ Reduction of myocardial infarct size in rabbits by ramiprilat: reversal by the bradykinin antagonist HOE 140. J Cardiovasc Pharmacol1993;21:996-1003.

Hartman JC , Kurc GM , Hullinger TG , Wall TM , Sheehy RM , Shebuski RJ Inhibition of nitric oxide synthase prevents myocardial protection by ramipril . J Pharmacol Exp Ther1994;3:1071-6.

Liang C-S. , Gavras H. , Black J. , Sherman LG , Hood Jr. WB Renin-angiotensin system inhibition in acute myocardial infarction in dogs. Effects on systemic hemodynamics, myocardial blood flow, segmental myocardial function and infarct size. Circulation1982 ;66:1249-55.

Daniell HB , Carson RR , Ballard KD , Thomas GR , Privitera PJ Effects of captopril on limiting infarct size in conscious dogs. J Cardiovasc Pharmacol1984;6:1043-7.

Jalowy A. , Schulz R. , Heusch G. AT1 receptor blockade in experimental myocardial ischemia/reperfusion . Basic Res Cardiol1998;93 (Suppl 2):85-91.

Seyedi N. , Xu XB , Nasjletti A. , Hintze TH Coronary kinin generation mediates nitric oxide release after angiotensin receptor stimulation. Hypertension1995;26:164-70.

de Carvalho Frimm C. , Sun Y. , Weber KT Angiotensin II receptor blockade and myocardial fibrosis of the infarcted rat heart. J Lab Clin Med1997;129:439-46.

Gaussin V. , Schneider MD Surviving infarction one gene at a time. Decreased remodeling and mortality in engineered mice lacking the angiotensin II type 1A receptor. Circulation1999;100:2043-4.

Harada K. , Sugaya T. , Murakami K. , Yazaki Y. , Komuro I. Angiotensin II type 1A receptor knockout mice display less left ventricular remodeling and improved survival after myocardial infarction. Circulation1999;100:2093-9.

Yamagishi H. , Kim S. , Nishikimi T. , Takeuchi K. , Takeda T. Contribution of cardiac renin-angiotensin system to ventricular remodelling in myocardial-infarcted rats. J Mol Cell Cardiol1993;25:1369-80.

Nishikimi T. , Yamagishi H. , Takeuchi K. , Takeda T. An angiotensin II receptor antagonist attenuates left ventricular dilatation after myocardial infarction in hypertensive rats . Cardiovasc Res1995;29:856-61.

Schieffer B. , Wirger A. , Meybrunn M. et al. Comparative effects of chronic angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade on cardiac remodeling after myocardial infarction in the rat. Circulation1994;89:2273-82.

KohyaT. , Yokoshiki H. , Tohse N. et al. Regression of left ventricular hypertrophy prevents ischemia-induced lethal arrhythmias. Beneficial effect of angiotensin II blockade. Circ Res1995;76:892-9.

Gervais M. , Richer C. , Fornes P. , de Gasparo M. , Giudicelli J-F. Valsartan and coronary haemodynamics in early post-myocardial infarction in rats. Fundam Clin Pharmacol1999;13:635-45.

van Kats JP , Duncker DJ , Haitsma DB et al. Angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade prevent cardiac remodeling in pigs after myocardial infarction. Role of tissue angiotensin II. Circulation2000;102:1556-63.

DuncanA-M , James GM , Anastasopoulos F. , KladisA , Briscoe TA , Campbell DJ Interaction between neutral endopeptidase and angiotensin converting enzyme inhibition in rats with myocardial infarction: Effects on cardiac hypertrophy and angiotensin and bradykinin peptide levels . J Pharmacol and Exper Ther1999;289:295-303.

Lefkowitz RJ , Rockman HA , Koch WJ Catecholamines, cardiac b-adrenergic receptors, and heart failure. Circulation2000;101:1634-7.

Spinale FG , Iannini JP , Mukherjee R. , Malton DM , de Gasparo M. Angiotensin AT1 receptor inhibition, angiotensin-converting enzyme inhibition, and combination therapy with developing heart failure: Cellular mechanisms of action. J Card Fail1998;4:325-32.

Spinale FG , de Gasparo M. , Whitebread S. et al. Modulation of the renin-angiotensin pathway through enzyme inhibition and specific receptor blockade in pacing-induced heart failure I. Effects on left ventricular performance and neurohormonal systems. Circulation1997;96:2385-96.

Krombach RS , Clair MJ , Hendrick JW et al. Angiotensin converting enzyme inhibition, AT1 receptor inhibition, and combination therapy with pacing induced heart failure: effects on left ventricular performance and regional blood flow patterns . Cardiovasc Res1998;38:631-45.

The Acute Infarction Ramipril Efficacy (AIRE) Investigators: Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet1993;342:821-8.

Pfeffer MA , Braunwald E. , Moye LA et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med1992;327:669-77.

Pitt B. , Segal R. , Martinez FA et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of losartan in the elderly study, ELITE) . Lancet1997;349:747-52.

Pitt B. , Poole-Wilson PA , Segal R. et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial - the losartan heart failure survival study ELITE II. Lancet2000;355:1582-7.

McKelvie RS , Yusuf S. , Pericak D. et al. Comparison of candesartan, enalapril, and their combination in congestive heart failure. Circulation1999;100:1056-64.